ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد ایتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Tamoxifen: Drug information

Tamoxifen: Drug information
(For additional information see "Tamoxifen: Patient drug information" and see "Tamoxifen: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
ALERT: US Boxed Warning
Uterine malignancies and thromboembolic events:

Serious and life-threatening events from the use of tamoxifen include uterine malignancies, stroke, and pulmonary embolism. Fatal cases of each type of event have occurred.

Incidence rates per 1,000 woman-years for these events were estimated from the National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 trial in women at high risk for breast cancer:

  • Endometrial adenocarcinoma: 2.20 for tamoxifen versus 0.71 for placebo

  • Uterine sarcoma: 0.17 for tamoxifen versus 0.04 for placebo

  • Stroke: 1.43 for tamoxifen versus 1.00 for placebo.

  • Pulmonary embolism: 0.75 for tamoxifen versus 0.25 for placebo

Discuss the potential benefits of tamoxifen versus the potential risks of these serious events with women at high risk for breast cancer and women with ductal carcinoma in situ (DCIS) considering tamoxifen to reduce the risk of developing breast cancer. For most patients already diagnosed with breast cancer, the benefits of tamoxifen outweigh its risks.

Brand Names: US
  • Soltamox
Brand Names: Canada
  • APO-Tamox;
  • Nolvadex D;
  • TEVA-Tamoxifen
Pharmacologic Category
  • Antineoplastic Agent, Estrogen Receptor Antagonist;
  • Selective Estrogen Receptor Modulator (SERM)
Dosing: Adult

Note: For the treatment of breast cancer, patients receiving both tamoxifen and chemotherapy should receive treatment sequentially, with tamoxifen following completion of chemotherapy.

Breast cancer, risk reduction (pre- and postmenopausal high-risk females): Oral: 20 mg once daily for 5 years.

Breast cancer, treatment: Oral:

Adjuvant therapy: 20 mg once daily

Duration of therapy: The American Society of Clinical Oncology (ASCO) guidelines for Adjuvant Endocrine Therapy of Hormone-Receptor Positive Breast Cancer (Focused Update) recommend the following durations of therapy based on menopausal status (Burstein 2014):

Pre- or perimenopausal at endocrine therapy initiation: Tamoxifen for an initial duration of 5 years; if pre- or perimenopausal (or status cannot be determined) after 5 years of therapy, may continue tamoxifen for a total duration of 10 years. If postmenopausal after 5 years of tamoxifen therapy, may continue tamoxifen for a total duration of 10 years, or switch to an aromatase inhibitor (AI) for up to a total duration of 10 years of endocrine therapy.

Postmenopausal at endocrine therapy initiation: Tamoxifen for a total duration of 10 years or tamoxifen for an initial duration of 5 years, followed by an AI for up to 5 years (for a total duration of 10 years of endocrine therapy) or tamoxifen for 2 to 3 years, followed by an AI for up to 5 years (for a total duration of 7 to 8 years of endocrine therapy) or an AI for 5 years.

Ductal carcinoma in situ (DCIS) (females), to reduce the risk for invasive breast cancer: 20 mg once daily for 5 years.

Metastatic: 20 mg once daily. Although the manufacturer's labeling recommends dosing of 20 to 40 mg daily (with doses >20 mg administered in 2 divided doses), clinical benefit has not been demonstrated with doses above 20 mg daily (Bratherton 1984).

Guideline recommendations: The American Society of Clinical Oncology (ASCO) guidelines for Endocrine Therapy for Hormone-Receptor Positive Metastatic Breast Cancer recommend the following based on menopausal status (Rugo 2016):

Premenopausal: Tamoxifen (in combination with ovarian suppression) may be offered as first-line therapy in patients with no prior endocrine therapy or in those who have received prior treatment with ovarian suppression and an AI; tamoxifen (with continued ovarian suppression) may also be offered as second-line therapy. Tamoxifen alone may be considered, but combination therapy is preferred.

Postmenopausal: Tamoxifen may be offered as second-line therapy in patients with no prior endocrine therapy. In patients who have received prior endocrine therapy with tamoxifen, tamoxifen may be offered first- or second-line in patients with late relapse (>12 months since adjuvant therapy). In patients who have received prior endocrine therapy with an AI, tamoxifen may be offered as first- or second-line therapy.

Duration of therapy: Continue tamoxifen treatment until documented disease progression (documented by imaging, clinical examination, or disease-related symptoms).

Endometrial carcinoma, recurrent, metastatic, or high-risk (endometrioid histologies only) (off-label use): Oral:

Monotherapy: 20 mg twice daily until disease progression or unacceptable toxicity (Thigpen 2001).

Combination therapy: 20 mg twice daily for 3 weeks (alternating with megestrol acetate every 3 weeks); continue alternating until disease progression or unacceptable toxicity) (Fiorica 2004).

Gynecomastia (off-label use): Oral: 20 mg once daily for up to 12 months (Boccardo 2005; Fradet 2007). The majority of published experiences have been in adult males with prostate cancer receiving bicalutamide. Use has also been reported in patients with idiopathic gynecomastia.

Idiopathic male infertility (off label use): Oral: 20 to 30 mg once daily for 3 to 6 months, then proceed to assisted reproductive therapy if pregnancy has not been achieved (Chua 2013; Colpi 2018).

Induction of ovulation (in breast cancer patients) (off-label use): Oral: 60 mg daily starting on the second or third day of the menstrual cycle (in combination with low-dose follicle-stimulating hormone [FSH]), and continued until the day of hCG administration (Oktay 2005).

Mastalgia, severe (off-label use): Oral: 10 mg once daily for 3 months; may consider further treatment if relapse occurs (Fentiman 1988).

Ovarian cancer, advanced and/or recurrent (off-label use): Oral: 20 mg twice daily (Hatch 1991; Markman 1996).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Chronic dialysis: No dosage adjustment necessary (Janus 2013).

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Dosing: Pediatric

(For additional information see "Tamoxifen: Pediatric drug information")

McCune-Albright syndrome; precocious puberty: Limited data available: Children 2 to 10 years: Oral: 20 mg once daily; dosing based on a trial of 25 girls ≤10 years of age (range: 2.9 to 10.9 years) who received treatment for 1 year; frequency of vaginal bleeding episodes were decreased; growth velocity was significantly decreased prior to pretreatment rates as was skeletal maturation; ovarian and uterine volumes were increased; further studies are needed (Eugester 2003)

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer’s labeling (not studied).

Chronic dialysis: No dosage adjustment necessary based on experience in adult patients (Janus 2013).

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer’s labeling; the effect of hepatic dysfunction on tamoxifen pharmacokinetics has not been determined.

Dosing: Older Adult

Refer to adult dosing.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Oral:

Soltamox: 10 mg/5 mL (150 mL) [sugar free; contains alcohol, usp, propylene glycol; licorice flavor]

Soltamox: 10 mg/5 mL (150 mL) [sugar free; contains alcohol, usp, propylene glycol; licorice-aniseed flavor]

Tablet, Oral:

Generic: 10 mg, 20 mg

Generic Equivalent Available: US

May be product dependent

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Nolvadex D: 20 mg

Generic: 10 mg, 20 mg

Medication Guide and/or Vaccine Information Statement (VIS)

An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication when used in females for breast cancer prevention or treatment of ductal carcinoma in situ:

Soltamox:https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021807lblMG.pdf

Administration: Adult

Oral: Administer tablets or oral solution orally with or without food. Use supplied dosing cup for oral solution.

Administration: Pediatric

Oral: Administer tablets or oral solution with or without food; use supplied dosing cup for oral solution.

Hazardous Drugs Handling Considerations

Hazardous agent (NIOSH 2016 [group 1]).

Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.

NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016).

Use: Labeled Indications

Breast cancer, risk reduction: Risk reduction in females at high risk: To reduce the incidence of breast cancer in adult females at high risk for breast cancer

Breast cancer, treatment:

Adjuvant treatment: Adjuvant treatment of adult patients with early stage estrogen receptor-positive breast cancer; to reduce the incidence of contralateral breast cancer in adult patients when used as adjuvant therapy for the treatment of breast cancer

Ductal carcinoma in situ: To reduce the risk of invasive breast cancer in adult females with ductal carcinoma in situ (following breast surgery and radiation)

Metastatic breast cancer: Treatment of adult patients with estrogen receptor-positive metastatic breast cancer

Use: Off-Label: Adult

Desmoid tumors, progressive or recurrent; Endometrial carcinoma, recurrent, metastatic, or high-risk (endometrioid histologies only); Gynecomastia; Idiopathic male infertility; Induction of ovulation (in breast cancer patients); Mastalgia, severe; Ovarian cancer, advanced and/or recurrent

Medication Safety Issues
Sound-alike/look-alike issues:

Tamoxifen may be confused with pentoxifylline, raloxifene, Tambocor, tamsulosin, temazepam, toremifene

High alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.

Adverse Reactions (Significant): Considerations
Hot flashes

Hot flashes commonly occur and can drastically affect the quality of life in females taking tamoxifen. Because many females will take tamoxifen for more than 5 years for the treatment or prevention of breast cancer, the risk of nonadherence or discontinuation related to this condition should be considered (Ref). Females who associate tamoxifen treatment with hot flashes are 3 to 4 times more likely to report severe symptoms (Ref). Severity of symptoms decline during the last 2 years of treatment and within 3 to 6 months after tamoxifen therapy is discontinued (Ref).

Mechanism: Non-dose-related; exact mechanism unknown; thought to be due to antiestrogen effects in the CNS affecting the regulation of core body temperature (Ref).

Onset: Varied; occurrence and severity increase over the first 3 months of therapy and remain consistent throughout therapy with highest rates (over 90%) in the first 2 years (Ref).

Risk factors:

• Premenopausal at diagnosis (Ref), younger age at menopause, history of naturally-occurring menopausal hot flashes prior to tamoxifen (Ref)

• Obesity (Ref)

• Smoking, caffeine, and alcohol (Ref)

• Depression and anxiety (Ref)

• Being employed (Ref)

• Previous chemotherapy (Ref)

Ocular effects

Ocular effects (including corneal deposits, cataract, epithelial keratopathy, macular edema, maculopathy, optic neuritis, retinal thrombosis, retinopathy, and vision color changes) have been reported in patients taking tamoxifen (Ref). An increased need for cataract surgery has also been reported (Ref).

Mechanism: Dose and time-related; retinal toxicity may occur due to axonal degeneration or a mechanism related to binding polar lipids resulting in drug-lipid accumulation (Ref). Chloride channel blockage in the lens has been proposed as the mechanism for cataract induction (Ref).

Onset: Variable; may occur at any time after tamoxifen initiation and may last after tamoxifen discontinuation (Ref). Most reports are after 2 years of treatment (Ref).

Risk factors:

• Long duration of therapy (Ref).

• While extremely high doses (240 to 320 mg/day) have been linked to ocular toxicity, doses ranging from 20 to 40 mg/day are also associated with visual function abnormalities and ocular effects (Ref)

Thromboembolic events

Serious and life-threatening thromboembolic events (some fatal) have occurred with tamoxifen, including cerebrovascular accident (stroke), deep vein thrombosis (DVT), and pulmonary embolism (PE). Risk normalized after discontinuation of therapy (Ref).

Mechanism: Dose-related; not clearly understood; proposed that estrogenic effects increase the risk. Influences anticoagulant proteins, such as antithrombin, protein S, and protein C similar to postmenopausal estrogen (Ref).

Onset: Delayed; PE events occurred at an average of 27 months after tamoxifen initiation (range: 2 to 60 months). DVT occurred at an average of 19 months (range: 2 to 57 months). Stroke occurred at an average of 30 months (range: 1 to 63 months).

Risk factors:

• Coadministration with chemotherapy

• Doses ≥20 mg/day (Ref)

• Age >49 years (Ref)

• First 24 months of use (Ref)

• High BMI (≥25 kg/m2) (Ref)

• History of surgery, fracture, and immobilization (Ref)

• Factor V Leiden mutations (Ref)

• Smoking (Ref)

• Personal history/family history of venous thromboembolism (Ref)

• Elevated blood pressure or cholesterol (Ref)

Uterine malignancies

Uterine malignancies have been reported with tamoxifen, including fatal cases of endometrial carcinoma and uterine carcinoma (sarcoma). The increased risk of endometrial cancer continues during therapy with tamoxifen but decreases after treatment discontinuation (Ref).

Mechanism: Dose- and time-related; in postmenopausal uterine and endometrial tissue, the estrogenic effects of tamoxifen are associated with endometrial polyp formation, endometrial hyperplasia, and uterine fibroids which lead to increased risk of endometrial carcinoma and uterine sarcoma (Ref). Other mechanisms related to biomolecular pathways and signaling pathways have been suggested (Ref).

Onset: Delayed; endometrial carcinoma has been reported as early as 6 months after initiation to 6 years after discontinuing tamoxifen (Ref). Uterine sarcomas have been reported to develop a median of 6 to 9 years after initiation of tamoxifen, with a case developing 20 years after initiation of therapy (Ref).

Risk factors:

• Cumulative dose (Ref)

• Prior estrogen replacement therapy (Ref)

• Obesity (Ref)

• History of endometrial abnormalities (Ref)

• Duration of therapy of ≥2 years (Ref)

• Postmenopausal females, especially those without hysterectomy and >49 years of age (Ref).

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%:

Cardiovascular: Flushing (33%), hypertension (11%), peripheral edema (11%), vasodilation (41%)

Dermatologic: Skin changes (6% to 19%), skin rash (13%)

Endocrine & metabolic: Amenorrhea (16%), fluid retention (32%), hot flash (19% to 80% [placebo: 8% to 68%]), weight loss (23%)

Gastrointestinal: Nausea (5% to 26%), nausea and vomiting (12%)

Genitourinary: Irregular menses (13% to 25%), vaginal discharge (12% to 55%), vaginal hemorrhage (6% to 23%)

Hematologic & oncologic: Lymphedema (11%)

Nervous system: Depression (2% to 12%), fatigue, mood changes (12% to 18%), pain (3% to 16%)

Neuromuscular & skeletal: Arthralgia (11%), arthritis (14%), asthenia

Respiratory: Pharyngitis (14%)

1% to 10%:

Cardiovascular: Chest pain (5%), deep vein thrombosis (≤2% [placebo: 0.2% to 0.3%]), edema (4%), ischemic heart disease (3%), venous thromboembolism (5%)

Dermatologic: Alopecia (5%), diaphoresis (6%)

Endocrine & metabolic: Hypercholesterolemia (3%), infrequent uterine bleeding (9%), menstrual disease (6%), ovarian cyst (3%), weight gain (9%)

Gastrointestinal: Abdominal cramps (1%), abdominal pain (9%), anorexia (1%), constipation (4% to 8%), diarrhea (7%), dyspepsia (6%)

Genitourinary: Leukorrhea (9%), mastalgia (6%), urinary tract infection (10%), vaginitis (5%), vulvovaginitis (5%)

Hematologic & oncologic: Anemia (5%), neoplasm (5%; second primary), thrombocytopenia (2% to 10%)

Hepatic: Increased serum aspartate aminotransferase (5%), increased serum bilirubin (2%)

Hypersensitivity: Hypersensitivity reaction (3%)

Infection: Infection, sepsis

Nervous system: Anxiety (6%), dizziness (8%), headache (8%), insomnia (9%), paresthesia (5%)

Neuromuscular & skeletal: Arthropathy (5%), back pain (10%), bone fracture (7%; premenopausal increased risk) (Kyvernitakis 2018), musculoskeletal pain (3%), myalgia (5%), ostealgia (6%), osteoporosis (7%)

Ophthalmic: Cataract (8% [placebo: 7%])

Renal: Increased serum creatinine (2%)

Respiratory: Bronchitis (5%), cough (4% to 9%), dyspnea (8%), flu-like symptoms (6%), sinusitis (5%), throat irritation (oral solution: 5%)

Miscellaneous: Cyst (5%)

<1%:

Cardiovascular: Cerebrovascular accident (Fisher 2005; Lai 2017), pulmonary embolism (placebo: 0.09% to 0.2%), superficial thrombophlebitis

Hematologic & oncologic: Endometrial carcinoma (Cohen 1996; Fisher 2005)

Hepatic: Hepatic neoplasm

Postmarketing:

Cardiovascular: Portal vein thrombosis (Hsu 2015), retinal thrombosis (Demirci 2019; Onder 2013)

Dermatologic: Bullous pemphigoid, cutaneous lupus erythematosus (Andrew 2014), erythema multiforme, night sweats (Day 2001; Moon 2017), pruritus vulvae (Day 2001), Stevens-Johnson syndrome, toxic epidermal necrolysis (Madabhavi 2015)

Endocrine & metabolic: Decreased libido (Morales 2004; Mourits 2002), hypercalcemia (Legha 1981; Nikolic-Tomasevic 2001), hyperglycemia (Hozumi 1997; Kim 2014), hypertriglyceridemia (Liu 2003; Singh 2016), loss of libido (males) (Pemmaraju 2012; Wibowo 2016)

Gastrointestinal: Cholestasis (Blackburn 1984), dysgeusia (Schiffman 2018), pancreatitis (Singh 2016; Tey 2019)

Genitourinary: Dyspareunia (Mourits 2002), endometrial hyperplasia (Cheng 1997; Lindahl 2008), endometrial polyps (Cohen 1996; Neven 1998), endometriosis (Kraft 2006), impotence (Pemmaraju 2012), vaginal dryness (Mortimer 1999; Mourits 2002)

Hematologic & oncologic: Agranulocytosis (Ching 1992; Herrscher 2020), leukopenia, malignant neoplasm of ovary (Cohen 1996; Ohara 2002), malignant neoplasm of uterus (Kloos 2002; Yildirim 2005), neutropenia (Herrscher 2020), pancytopenia (Mitani 2006), tumor flare (during treatment of metastatic breast cancer; generally resolves with continuation; includes increased lesion size and erythema) (Mulvenna 1999; Plotkin 1978), tumor lysis syndrome (Cech 1986), uterine carcinoma (sarcoma), uterine fibroids (Polin 2008)

Hepatic: Hepatic necrosis (Ching 1992; Storen 2000), hepatitis (Oien 1999; Pinto 1995), liver steatosis (Roy 2019; Saphner 2009)

Hypersensitivity: Angioedema (Bork 2017; Rousset-Jablonski 2009)

Nervous system: Tumor pain (during treatment of metastatic breast cancer; generally resolves with continuation) (Mulvenna 1999)

Neuromuscular & skeletal: Subacute cutaneous lupus erythematosus (Andrew 2014)

Ophthalmic: Corneal deposits (Muftuoglu 2006; Tarafdar 2012), epithelial keratopathy (Noureddin 1999; Pavlidis 1992), macular edema (Murray 1998; Zafeiropoulos 2014), maculopathy (Bommireddy 2016; Srikantia 2010), optic neuritis (Colley 2004; Noureddin 1999), retinal hole without detachment (macula hole) (Cronin 2005), retinal pigment changes (Noureddin 1999), retinopathy (Georgalas 2013; Wang 2015), vision color changes (Eisner 2011; Salomao 2007)

Respiratory: Eosinophilic pneumonitis (Kwon 2019), interstitial pneumonitis (Ahmed 2016), pulmonary fibrosis (Bentzen 1996), pulmonary injury (Etori 2017)

Contraindications

Known hypersensitivity (eg, angioedema, serious skin reactions) to tamoxifen or any component of the formulation; concurrent warfarin therapy or history of deep vein thrombosis or pulmonary embolism (when tamoxifen is used for breast cancer risk reduction in women at high risk for breast cancer or risk reduction of invasive breast cancer after treatment of ductal carcinoma in situ [DCIS]).

Canadian labeling: Additional contraindications (not in the US labeling): History of stroke or at increased risk for developing endometrial cancer (when used in the prevention setting [not approved indication]); pregnancy.

Warnings/Precautions

Disease-related concerns:

• Bone mineral density: Tamoxifen use may be associated with changes in bone mineral density (BMD) and the effects may be dependent upon menstrual status. In postmenopausal women, tamoxifen use is associated with a protective effect on BMD, preventing loss of BMD which lasts over the 5-year treatment period. In premenopausal women, a decline (from baseline) in BMD mineral density has been observed in women who continued to menstruate; may be associated with an increased risk of fractures.

• Hyperlipidemia: Hypercholesterolemia and postmarketing cases of hyperlipidemias have been reported. Periodic monitoring of cholesterol and triglycerides may be indicated in patients with preexisting hyperlipidemias.

• Metastatic breast cancer: Local disease flare and increased bone and tumor pain may occur; may be associated with (good) tumor response; onset is shortly after therapy initiation and usually resolves rapidly. In some patients with bone metastasis, hypercalcemia has occurred, usually within a few weeks of therapy initiation. Institute appropriate hypercalcemia management; discontinue tamoxifen if hypercalcemia is severe.

Concurrent drug therapy issues:

• Selective serotonin reuptake inhibitors (SSRI): Concomitant use with select SSRIs may result in decreased tamoxifen efficacy. Strong CYP2D6 inhibitors (eg, fluoxetine, paroxetine) are reported to interfere with transformation to the active metabolite endoxifen; when possible, select alternative medications with minimal or no impact on endoxifen levels (Sideras 2010). Weak CYP2D6 inhibitors (eg, venlafaxine, citalopram) have minimal effect on the conversion to endoxifen (Jin 2005); escitalopram is also a weak CYP2D6 inhibitor. In a retrospective analysis of breast cancer patients taking tamoxifen and SSRIs, concomitant use of paroxetine and tamoxifen was associated with an increased risk of death due to breast cancer (Kelly 2010).

Special populations:

• CYP2D6 poor metabolizers: Lower plasma concentrations of endoxifen (active metabolite) have been observed in patients with reduced CYP2D6 activity (Jin 2005; Schroth 2009) and may be associated with reduced efficacy, although data is conflicting. Routine CYP2D6 testing is not recommended at this time in order to determine optimal endocrine therapy (Visvanathan 2009).

Dosage form specific issues:

• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).

Warnings: Additional Pediatric Considerations

Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, >3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP, 1997; Shehab, 2009).

Metabolism/Transport Effects

Substrate of CYP2A6 (minor), CYP2B6 (minor), CYP2C9 (minor), CYP2D6 (major), CYP2E1 (minor), CYP3A4 (major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; Inhibits CYP2C9 (weak)

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Anastrozole: Tamoxifen may decrease the serum concentration of Anastrozole. Risk X: Avoid combination

Artemether and Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Chloroquine: Tamoxifen may enhance the adverse/toxic effect of Chloroquine. Specifically, concomitant use of tamoxifen and chloroquine may increase the risk of retinal toxicity. Risk C: Monitor therapy

CYP2D6 Inhibitors (Moderate): May decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites. Management: Consider alternatives to the use of moderate CYP2D6 inhibitors with tamoxifen when possible, as the combination may be associated with reduced clinical effectiveness of tamoxifen. Risk D: Consider therapy modification

CYP2D6 Inhibitors (Strong): May decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites. Management: Avoid concurrent use of strong CYP2D6 inhibitors with tamoxifen when possible, as the combination may be associated with a reduced clinical effectiveness of tamoxifen. Risk D: Consider therapy modification

CYP3A4 Inducers (Moderate): May decrease serum concentrations of the active metabolite(s) of Tamoxifen. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tamoxifen. Risk C: Monitor therapy

CYP3A4 Inducers (Strong): May decrease serum concentrations of the active metabolite(s) of Tamoxifen. CYP3A4 Inducers (Strong) may decrease the serum concentration of Tamoxifen. Risk X: Avoid combination

Erdafitinib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Fluoroestradiol F18: Estrogen Receptor Antagonists may diminish the diagnostic effect of Fluoroestradiol F18. Management: Image patients with fluoroestradiol F-18 prior to starting systemic endocrine therapies that block the estrogen receptor. Use of fluoroestradiol F-18 should not delay indicated treatment. Risk D: Consider therapy modification

Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. Risk C: Monitor therapy

Hydroxychloroquine: Tamoxifen may enhance the adverse/toxic effect of Hydroxychloroquine. Specifically, concomitant use of tamoxifen and hydroxychloroquine may increase the risk of retinal toxicity. Risk C: Monitor therapy

Ivosidenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Risk C: Monitor therapy

Letrozole: Tamoxifen may decrease the serum concentration of Letrozole. Risk C: Monitor therapy

Mipomersen: Tamoxifen may enhance the hepatotoxic effect of Mipomersen. Risk C: Monitor therapy

Ospemifene: Selective Estrogen Receptor Modulators may enhance the adverse/toxic effect of Ospemifene. Ospemifene may also enhance adverse/toxic effects of other Selective Estrogen Receptor Modulators. Selective Estrogen Receptor Modulators may diminish the therapeutic effect of Ospemifene. Ospemifene may also diminish the therapeutic effects of other Selective Estrogen Receptor Modulators. Risk X: Avoid combination

Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

Ribociclib: May increase the serum concentration of Tamoxifen. Management: Concurrent use of ribociclib with tamoxifen is not indicated. Use of this combination may increase the effects and toxicities of tamoxifen. Risk D: Consider therapy modification

TOLBUTamide: CYP2C9 Inhibitors (Weak) may increase the serum concentration of TOLBUTamide. Risk C: Monitor therapy

Vitamin K Antagonists (eg, warfarin): Tamoxifen may increase the serum concentration of Vitamin K Antagonists. Risk X: Avoid combination

Food Interactions

Grapefruit juice may decrease the metabolism of tamoxifen. Management: Monitor for increased effects/toxicity with concomitant use.

Reproductive Considerations

Evaluate pregnancy status prior to use in patients who may become pregnant. Treatment should be initiated during menstruation or immediately after a negative pregnancy test.

Patients who may become pregnant should use effective nonhormonal contraception or barrier contraceptives during tamoxifen therapy. Recommendations for how long contraception should continue once tamoxifen is discontinued vary. The US product labeling recommends contraception be continued for 2 months following the last tamoxifen dose; other sources suggest contraception be continued for 3 to 6 months (ESMO [Lambertini 2020]; ESMO [Peccatori 2013]) or longer (Nolvadex-D Canadian product monograph).

Tamoxifen may induce ovulation (Steiner 2005) or cause menstrual cycle irregularities. Based on animal data, tamoxifen may impair embryo implantation in patients who may become pregnant, but may not reliably cause infertility, even if menstrual cycles are irregular.

Use of tamoxifen has been considered for the treatment of idiopathic male infertility; however, benefits may be limited (ASRM [Schlegel 2021]; Colpi 2018).

Pregnancy Considerations

Based on the mechanism of action, and data from animal reproduction studies, in utero exposure to tamoxifen may cause fetal harm. However, available data are insufficient to establish a causal relationship; no pattern of birth defects has been observed, and the long-term effects of tamoxifen on development are not known (Braems 2011; Buonomo 2020; Schuurman 2019). There have been reports of vaginal bleeding, birth defects, spontaneous abortions and fetal death following use in pregnancy. Tamoxifen use during pregnancy may have a potential long-term risk to the fetus of a diethylstilbestrol (DES)-like syndrome (based on animal data).

The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy; the guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team). Use of tamoxifen during pregnancy is contraindicated (ESMO [Peccatori 2013]).

A long-term observational research study is collecting information about the diagnosis and treatment of cancer during pregnancy. For additional information about the pregnancy and cancer registry or to become a participant, contact Cooper Health (1-877-635-4499).

Breastfeeding Considerations

Tamoxifen is present in breast milk (Peccatori 2020).

The presence of tamoxifen in breast milk was evaluated in a breastfeeding woman diagnosed with breast cancer. Breast milk samples were collected prior to the first dose and over the next 23 days of therapy (total 39 samples). Tamoxifen was present in breast milk after the first dose and concentrations significantly increased over 3 weeks. The N-desmethyl tamoxifen metabolite was detected in breast milk by day 6 and concentrations also increased over time. Two other active metabolites were also present. Tamoxifen concentrations in the maternal plasma were not evaluated and steady state concentrations were likely not reached; therefore, breast milk concentrations may have continued to rise. Authors of the study concluded clinically significant concentrations of tamoxifen are likely present in breast milk (Peccatori 2020).

Tamoxifen has been shown to inhibit early postpartum milk production; effects on established milk production is not known. Breastfeeding during tamoxifen therapy is contraindicated by some guidelines (ABM [Johnson 2020]). Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during treatment and for 3 months following the last tamoxifen dose.

Monitoring Parameters

CBC with platelets, serum calcium, liver function tests; triglycerides and cholesterol (in patients with preexisting hyperlipidemias); INR and PT (in patients on vitamin K antagonists); pregnancy test (prior to treatment in females of reproductive potential); monitor for and promptly evaluate abnormal vaginal bleeding, menstrual irregularities, changes in vaginal discharge, or pelvic pain/pressure; breast exam (baseline and routine), gynecologic exam (baseline and annually, continuing after discontinuation of therapy), mammogram (baseline and routine); signs/symptoms of thromboembolism (eg, stroke, DVT [leg swelling, tenderness], or PE [shortness of breath]); ophthalmic exam (if vision problem or cataracts); bone mineral density (premenopausal women). Monitor adherence.

Mechanism of Action

Tamoxifen is a selective estrogen receptor modulator (SERM) that competitively binds to estrogen receptors on tumors and other tissue targets, producing a nuclear complex that decreases DNA synthesis and inhibits estrogen effects; nonsteroidal agent with potent antiestrogenic properties which compete with estrogen for binding sites in breast and other tissues; cells accumulate in the G0 and G1 phases; therefore, tamoxifen is cytostatic rather than cytocidal.

Pharmacokinetics

Absorption: Well absorbed

Distribution: Widely distributed to most tissues, particularly tissues that inhibit estrogen receptors (Perry 2012)

Protein binding: Highly protein bound (Perry 2012)

Metabolism: Hepatic; via CYP2D6 to 4-hydroxytamoxifen and via CYP3A4/5 to N-desmethyl-tamoxifen. Each is then further metabolized into endoxifen (4-hydroxy-tamoxifen via CYP3A4/5 and N-desmethyl-tamoxifen via CYP2D6); both 4-hydroxy-tamoxifen and endoxifen are 30- to 100-fold more potent than tamoxifen

Bioavailability: Tamoxifen oral solution is bioequivalent to tamoxifen tablets

Half-life elimination: Tamoxifen: ~5 to 7 days; N-desmethyl tamoxifen: ~14 days

Time to peak, serum:

Children 2 to 10 years (female): ~8 hours

Adults: ~5 hours

Excretion: ~65% (primarily fecal); <30% as unchanged drug and unconjugated metabolites

Clearance: Higher (~2.3-fold) in female pediatric patients (2 to 10 years) compared to adult breast cancer patients; within pediatric population, clearance faster in children 2 to 6 years compared to older children

Pricing: US

Solution (Soltamox Oral)

10 mg/5 mL (per mL): $5.54

Tablets (Tamoxifen Citrate Oral)

10 mg (per each): $1.89

20 mg (per each): $3.79

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Brand Names: International
  • Apo-Tamox (HK);
  • Bilem (TH);
  • Citofen (HR);
  • Crisafeno (PY);
  • Cytotam (LK);
  • Cytotam-10 (ET);
  • Diemon (AR);
  • Fenahex (PH);
  • Genox (AU, NZ);
  • Ginarsan (PE);
  • Ginarsan Forte (PE);
  • Gynatam (PH);
  • Gyraxen (PH);
  • Kessar (CL, FR, GR, IT, ZA);
  • Mamofen (IN, LK);
  • Medtax (PH);
  • Moxafen (AE, BH, CY, IQ, IR, JO, KR, KW, LY, OM, SA, SY, YE);
  • Neophedan (ZA);
  • Neophedan-10 (ZW);
  • Nolvadex (AE, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CI, CL, CR, CY, DE, DO, EG, ES, ET, FI, FR, GH, GM, GN, GR, GT, GY, HK, HN, HR, IE, IN, IQ, IR, IT, JM, JO, KE, KR, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, NE, NG, NI, NL, NO, OM, PA, PK, PL, PR, PT, QA, SA, SC, SD, SE, SG, SL, SN, SR, SV, SY, TN, TR, TT, TW, TZ, UG, VE, VN, YE, ZM, ZW);
  • Nolvadex D (LB, LK, MT);
  • Nolvadex-D (CO, CU, EE, PH, PY, SG, TH, UY);
  • Novofen (EC, SG, TH, TW);
  • Novofen Forte (BZ, GY, SR);
  • Novofen-D (BB, BM, BS, BZ, GY, JM, NL, PR, SR, TT);
  • Oncotamox (EC);
  • Retaxim (HR);
  • Soltamox (GB, IE);
  • Tadex (FI, TW);
  • Tamec (CH);
  • Tamifen (AE, BH, CY, IQ, IR, JO, KW, LY, OM, SA, SY, YE);
  • Tamifine (VN);
  • Tamizam (BE, LU);
  • Tamodex (EG);
  • Tamofen (CN, DK, FI, HK);
  • Tamofon (AE, JO);
  • Tamona (BD);
  • Tamophar (AE, BH, KW, QA, SA);
  • Tamoplex (BE, KR, PE, PH, ZA);
  • Tamorex (KR);
  • Tamosin (AU);
  • Tamox (IE);
  • Tamoxen (AU, BD, PH);
  • Tamoxifen-Eurogenerics (LU);
  • Tamoxifen-Hexal (LU);
  • Tamoxifen-ratioparm (LU);
  • Tamoxifen-Teva (HU);
  • Tamoxifen-Zeneca (LU);
  • Tamoxin (EG);
  • Tamoxis (LK);
  • Tamoxit (LB);
  • Taxus (EC, PE);
  • Tecnofen (MX);
  • Temolex (BD);
  • Zitazonium (CZ, HU, PH, RU)


For country abbreviations used in Lexicomp (show table)
  1. Abramson N, Costantino JP, Garber JE, Berliner N, Wickerham DL, Wolmark N. Effect of factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. J Natl Cancer Inst. 2006;98(13):904‐910. doi:10.1093/jnci/djj262 [PubMed 16818854]
  2. Adamopoulos DA, Nicopoulou S, Kapolla N, Karamertzanis M, Andreou E. The combination of testosterone undecanoate with tamoxifen citrate enhances the effects of each agent given independently on seminal parameters in men with idiopathic oligozoospermia. Fertil Steril. 1997;67(4):756-762. [PubMed 9093207]
  3. Adamopoulos DA, Nicopoulou S, Kapolla N, Vassilopoulos P, Karamertzanis M, Kontogeorgos L. Endocrine effects of testosterone undecanoate as a supplementary treatment to menopausal gonadotropins or tamoxifen citrate in idiopathic oligozoospermia. Fertil Steril. 1995;64(4):818-824. [PubMed 7672156]
  4. Adamopoulos DA, Pappa A, Billa E, Nicopoulou S, Koukkou E, Michopoulos J. Effectiveness of combined tamoxifen citrate and testosterone undecanoate treatment in men with idiopathic oligozoospermia. Fertil Steril. 2003;80(4):914-920. doi:10.1016/s0015-0282(03)01123-3 [PubMed 14556812]
  5. Ahmed S, Shahid RK. Acute interstitial pneumonitis following adjuvant tamoxifen therapy. J Clin Oncol. 2009;27(15 suppl):e11637-e11637.
  6. AinMelk Y, Belisle S, Carmel M, Jean-Pierre T. Tamoxifen citrate therapy in male infertility. Fertil Steril. 1987;48(1):113-117. [PubMed 3297810]
  7. Andrew P, Valiani S, MacIsaac J, Mithoowani H, Verma S. Tamoxifen-associated skin reactions in breast cancer patients: from case report to literature review. Breast Cancer Res Treat. 2014;148(1):1-5. doi:10.1007/s10549-014-3150-0 [PubMed 25292419]
  8. Archer DF, Sturdee DW, Baber R, et al. Menopausal hot flushes and night sweats: where are we now?. Climacteric. 2011;14(5):515‐528. doi:10.3109/13697137.2011.608596 [PubMed 21848495]
  9. Behtash N, Hashemi R, Karimi Zarchi M. Uterine malignancy following tamoxifen use in breast cancer patients in Iran: case series and literature review. Asian Pac J Cancer Prev. 2009;10(1):163‐166. [PubMed 19469647]
  10. Bentzen SM, Skoczylas JZ, Overgaard M, Overgaard J. Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Natl Cancer Inst. 1996;88(13):918‐922. doi:10.1093/jnci/88.13.918 [PubMed 8656444]
  11. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet. 2000;356(9233):881‐887. doi:10.1016/s0140-6736(00)02677-5 [PubMed 11036892]
  12. Bernstein L, Deapen D, Cerhan JR, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst. 1999;91(19):1654‐1662. doi:10.1093/jnci/91.19.1654 [PubMed 10511593]
  13. Blackburn AM, Amiel SA, Millis RR, Rubens RD. Tamoxifen and liver damage. Br Med J (Clin Res Ed). 1984;289(6440):288. doi:10.1136/bmj.289.6440.288 [PubMed 6430441]
  14. Boccardo F, Rubagotti A, Battaglia M, et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol. 2005;23(4):808-815. [PubMed 15681525]
  15. Bommireddy T, Carrim ZI. To stop or not? Tamoxifen therapy for secondary prevention of breast cancer in a patient with ocular toxicity. BMJ Case Rep. 2016;2016:bcr2015213431. Published 2016 Jan 11. doi:10.1136/bcr-2015-213431 [PubMed 26759403]
  16. Bonneterre J, Thürlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study [published correction appears in J Clin Oncol. 2012 Jan 20;30(3):343]. J Clin Oncol. 2000;18(22):3748‐3757. doi:10.1200/JCO.2000.18.22.3748 [PubMed 11078487]
  17. Bork K, Wulff K, Witzke G, Rietz S, Hardt J. Tamoxifen may cause life-threatening angioedema attacks in patients with hereditary angioedema. J Eur Acad Dermatol Venereol. 2017;31(5):e237‐e239. doi:10.1111/jdv.14056 [PubMed 27878882]
  18. Braems G, Denys H, De Wever O, et al. Use of tamoxifen before and during pregnancy. Oncologist. 2011;16(11):1547-1551. doi: 10.1634/theoncologist.2011-0121. [PubMed 22020212]
  19. Bratherton DG, Brown CH, Bucha a R, et al, “A Comparison of Two Doses of Tamoxifen (Nolvadex) in Postmenopausal Women With Advanced Breast Cancer: 10 mg bd Versus 20 mg bd,” Br J Cancer, 1984, 50(2):199-205. [PubMed 6380554]
  20. Breznik R, Borko E. Effectiveness of antiestrogens in infertile men. Arch Androl. 1993;31(1):43-48. [PubMed 8373285]
  21. Buonomo B, Brunello A, Noli S, et al. Tamoxifen exposure during pregnancy: a systematic review and three more cases. Breast Care (Basel). 2020;15(2):148-156. doi:10.1159/000501473 [PubMed 32398983]
  22. Burstein HJ, Temin S, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255-2269. doi: 10.1200/JCO.2013.54.2258. [PubMed 24868023]
  23. Buvat J, Buvat-Herbaut M, Marcolin G, Ardaens-Boulier K. Antiestrogens as treatment of female and male infertilities. Horm Res. 1987;28(2-4):219-229. [PubMed 3331375]
  24. Cakmak H, Rosen MP. Ovarian stimulation in cancer patients. Fertil Steril. 2013;99(6):1476-1484. doi: 10.1016/j.fertnstert.2013.03.029. [PubMed 23635348]
  25. Cech P, Block JB, Cone LA, Stone R. Tumor lysis syndrome after tamoxifen flare. N Engl J Med. 1986;315(4):263‐264. doi:10.1056/NEJM198607243150417 [PubMed 3014336]
  26. Chen JY, Kuo SJ, Liaw YP, et al. Endometrial cancer incidence in breast cancer patients correlating with age and duration of tamoxifen use: a population based study. J Cancer. 2014;5(2):151‐155. doi:10.7150/jca.8412 [PubMed 24563669]
  27. Cheng WF, Lin HH, Torng PL, Huang SC. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol. 1997;66(2):233‐237. doi:10.1006/gyno.1997.4739 [PubMed 9264568]
  28. Ching CK, Smith PG, Long RG. Tamoxifen-associated hepatocellular damage and agranulocytosis. Lancet. 1992;339(8798):940. doi:10.1016/0140-6736(92)90991-b [PubMed 1348345]
  29. Chua ME, Escusa KG, Luna S, et al. Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: a meta-analysis. Andrology. 2013;1(5):749-757. doi: 10.1111/j.2047-2927.2013.00107.x. [PubMed 23970453]
  30. Cohen I, Altaras MM, Shapira J, et al. Time-dependent effect of tamoxifen therapy on endometrial pathology in asymptomatic postmenopausal breast cancer patients. Int J Gynecol Pathol. 1996;15(2):152‐157. doi:10.1097/00004347-199604000-00010 [PubMed 8786205]
  31. Colley SM, Elston JS. Tamoxifen optic neuropathy. Clin Exp Ophthalmol. 2004;32(1):105‐106. doi:10.1046/j.1442-9071.2004.00769.x [PubMed 14746604]
  32. Colpi GM, Francavilla S, Haidl G, et al. European Academy of Andrology guideline management of oligo-astheno-teratozoospermia. Andrology. 2018;6(4):513-524. doi:10.1111/andr.12502 [PubMed 30134082]
  33. Cronin BG, Lekich CK, Bourke RD. Tamoxifen therapy conveys increased risk of developing a macular hole. Int Ophthalmol. 2005;26(3):101‐105. doi:10.1007/s10792-005-5424-3 [PubMed 16983587]
  34. Curtis RE, Freedman DM, Sherman ME, Fraumeni JF Jr. Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. J Natl Cancer Inst. 2004;96(1):70‐74. doi:10.1093/jnci/djh007 [PubMed 14709741]
  35. Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;16(1):67‐75. doi:10.1016/S1470-2045(14)71171-4 [PubMed 25497694]
  36. Davies C, Godwin J, Gray R; Early Breast Cancer Trialists' Collaborative Group (EBCTCG), et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771‐784. doi:10.1016/S0140-6736(11)60993-8 [PubMed 21802721]
  37. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805-816. doi:10.1016/S0140-6736(12)61963-1 [PubMed 23219286]
  38. Day R; National Surgical Adjuvant Breast and Bowel Projet P-1 study (NSABP-1). Quality of life and tamoxifen in a breast cancer prevention trial: a summary of findings from the NSABP P-1 study. Ann N Y Acad Sci. 2001;949:143‐150. [PubMed 11795346]
  39. DeCensi A, Puntoni M, Guerrieri-Gonzaga A, et al. Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia. J Clin Oncol. 2019;37(19):1629‐1637. doi:10.1200/JCO.18.01779 [PubMed 30973790]
  40. Demirci NS, Erdem GU, Uçgun Nİ, et al. A rare case: Branch retinal vein occlusion associated with the use of tamoxifen. J Cancer Res Ther. 2019;15(3):722‐724. doi:10.4103/0973-1482.204888 [PubMed 31169251]
  41. Duggan C, Marriott K, Edwards R, Cuzick J. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol. 2003;21(19):3588‐3593. doi:10.1200/JCO.2003.10.111 [PubMed 14512389]
  42. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687‐1717. doi:10.1016/S0140-6736(05)66544-0 [PubMed 15894097]
  43. Eastell R, Adams JE, Coleman RE, et al, “Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230,” J Clin Oncol, 2008, 26(7):1051-7. [PubMed 18309940]
  44. Eisner A, Luoh SW. Breast cancer medications and vision: effects of treatments for early-stage disease. Curr Eye Res. 2011;36(10):867‐885. doi:10.3109/02713683.2011.594202 [PubMed 21819259]
  45. Etori S, Nakano R, Kamada H, et al. Tamoxifen-induced lung injury. Intern Med. 2017;56(21):2903‐2906. doi:10.2169/internalmedicine.8649-16 [PubMed 28943550]
  46. Eugster EA, Rubin SD, Reiter EO, et al, “Tamoxifen Treatment for Precocious Puberty in McCune-Albright Syndrome: A Multicenter Trial,” J Pediatr, 2003, 143(1):60-6. [PubMed 12915825]
  47. Fentiman IS, Caleffi M, Hamed H, et al. Dosage and duration of tamoxifen treatment for mastalgia: a controlled trial. Br J Sur. 1988;75(9):845-846. [PubMed 3052691]
  48. Fiorica JV, Brunetto VL, Hanjani P, et al, “Phase II trial of Alternating Courses of Megestrol Acetate and Tamoxifen in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study,” Gynecol Oncol, 2004, 92(1):10-4 [PubMed 14751131]
  49. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97(22):1652‐1662. doi:10.1093/jnci/dji372 [PubMed 16288118]
  50. Fleming CA, Heneghan HM, O'Brien D, McCartan DP, McDermott EW, Prichard RS. Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy. Br J Surg. 2018;105(9):1098‐1106. doi:10.1002/bjs.10899 [PubMed 29974455]
  51. Fradet Y, Egerdie B, Andersen M, et al. Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study. Eur Urol. 2007;52(1):106-114. [PubMed 17270340]
  52. Freedman AN, Yu B, Gail MH, et al. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older [published correction appears in J Clin Oncol. 2013 Nov 10;31(32):4167]. J Clin Oncol. 2011;29(17):2327‐2333. doi:10.1200/JCO.2010.33.0258 [PubMed 21537036]
  53. Garber JE, Halabi S, Tolaney SM, et al. Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer [published correction appears in J Natl Cancer Inst. 2010 Aug 4;102(15):1210. Paskett, Electra M [corrected to Paskett, Electra D]]. J Natl Cancer Inst. 2010;102(13):942‐949. doi:10.1093/jnci/djq211 [PubMed 20554945]
  54. Georgalas I, Paraskevopoulos T, Papaconstaninou D, Brouzas D, Koutsandrea C. Large bilateral foveal cysts in the inner retina of a patient treated with tamoxifen, diagnosed with Fourier-domain optical coherence tomography. Clin Ophthalmol. 2013;7:707‐709. doi:10.2147/OPTH.S38951 [PubMed 23630411]
  55. Goetz MP, Kamal A, and Ames MM, “Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response,” Clin Pharmacol Ther, 2008, 83(1):160-6. [PubMed 17882159]
  56. Hansmann A, Adolph C, Vogel T, et al, “High-Dose Tamoxifen and Sulindac as First-Line Treatment for Desmoid Tumors,” Cancer, 2004, 100(3):612-20. [PubMed 14745880]
  57. Hatch KD, Beecham JB, Blessing JA, et al, “Responsiveness of Patients With Advanced Ovarian Carcinoma to Tamoxifen. A Gynecologic Oncology Group Study of Second-Line Therapy in 10 Patients,” Cancer, 1991, 68(2):269-71. [PubMed 2070324]
  58. Hernandez RK, Sørensen HT, Pedersen L, Jacobsen J, Lash TL. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer. 2009;115(19):4442‐4449. doi:10.1002/cncr.24508 [PubMed 19569248]
  59. Herrscher H, Leblanc J, Petit T. Agranulocytosis induced by tamoxifen in a breast cancer patient. Breast Care (Basel). 2020;15(1):72‐74. doi:10.1159/000500708 [PubMed 32231501]
  60. Hozumi Y, Kawano M, Miyata M. Severe hypertriglyceridemia caused by tamoxifen-treatment after breast cancer surgery. Endocr J. 1997;44(5):745‐749. doi:10.1507/endocrj.44.745 [PubMed 9466333]
  61. Hsu A, Belkin E, Han S, Pellish R. Tamoxifen-associated portal vein thrombosis causing severe oesophageal variceal bleeding. BMJ Case Rep. 2015;2015:bcr2015209988. doi:10.1136/bcr-2015-209988 [PubMed 26315359]
  62. Hu R, Hilakivi-Clarke L, Clarke R. Molecular mechanisms of tamoxifen-associated endometrial cancer (Review). Oncol Lett. 2015;9(4):1495‐1501. doi:10.3892/ol.2015.2962 [PubMed 25788989]
  63. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics committee on drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
  64. Iqbal J, Ginsburg OM, Wijeratne TD, et al. Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review. Cancer Treat Rev. 2012;38(4):318‐328. doi:10.1016/j.ctrv.2011.06.009 [PubMed 21775065]
  65. Janus N, Launay-Vacher V, Thyss A, et al, “Management of Anticancer Treatment in Patients Under Chronic Dialysis: Results of the Multicentric CANDY (CANcer and DialYsis) Study,” Ann Oncol, 2013, 24(2):501-7. [PubMed 23038759]
  66. Jin Y, Desta Z, Stearns V, et al, “CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment,” J Natl Cancer Inst, 2005, 97(1):30-9. [PubMed 15632378]
  67. Jin Y, Hayes DF, Li L, et al. Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. J Clin Oncol. 2008;26(36):5849‐5854. doi:10.1200/JCO.2008.16.8377 [PubMed 19018086]
  68. Johnson HM, Mitchell KB; Academy of Breastfeeding Medicine. ABM Clinical Protocol #34: Breast cancer and breastfeeding. Breastfeed Med. 2020;15(7):429-434. doi:10.1089/bfm.2020.29157.hmj [PubMed 32516007]
  69. Jones ME, van Leeuwen FE, Hoogendoorn WE, et al. Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries. Breast Cancer Res. 2012;14(3):R91. doi:10.1186/bcr3206 [PubMed 22691381]
  70. Katase K, Sugiyama Y, Hasumi K, Yoshimoto M, Kasumi F. The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma. Cancer. 1998;82(9):1698‐1703. [PubMed 9576291]
  71. Kelly CM, Juurlink DN, Gomes T, et al, “Selective Serotonin Reuptake Inhibitors and Breast Cancer Mortality in Women Receiving Tamoxifen: A Population Based Cohort Study,” BMJ, 2010, 340:c693. [PubMed 20142325]
  72. Kim YA, Lee S, Jung JW, et al. Severe acute pancreatitis due to tamoxifen-induced hypertriglyceridemia with diabetes mellitus. Chin J Cancer Res. 2014;26(3):341‐344. doi:10.3978/j.issn.1000-9604.2014.05.01 [PubMed 25035662]
  73. Kligman L, Younus J. Management of hot flashes in women with breast cancer. Curr Oncol. 2010;17(1):81‐86. doi:10.3747/co.v17i1.473 [PubMed 20179808]
  74. Kloos I, Delaloge S, Pautier P, et al. Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: report of five cases and review of the literature. Int J Gynecol Cancer. 2002;12(5):496‐500. doi:10.1046/j.1525-1438.2002.01134.x [PubMed 12366669]
  75. Kraft JK, Hughes T. Polypoid endometriosis and other benign gynaecological complications associated with Tamoxifen therapy-a case to illustrate features on magnetic resonance imaging. Clin Radiol. 2006;61(2):198‐201. doi:10.1016/j.crad.2005.09.007 [PubMed 16439226]
  76. Krause W, Holland-Moritz H, Schramm P. Treatment of idiopathic oligozoospermia with tamoxifen—a randomized controlled study. Int J Androl. 1992;15(1):14-18. [PubMed 1544695]
  77. Kwon E, Kim M, Choi E, Park Y, Kim C. Tamoxifen-induced acute eosinophilic pneumonia in a breast cancer patient. Int J Surg Case Rep. 2019;60:186‐190. doi:10.1016/j.ijscr.2019.02.026 [PubMed 31229774]
  78. Kyvernitakis I, Kostev K, Hadji P. The tamoxifen paradox-influence of adjuvant tamoxifen on fracture risk in pre- and postmenopausal women with breast cancer. Osteoporos Int. 2018;29(11):2557-2564. doi:10.1007/s00198-018-4642-2 [PubMed 30032359]
  79. Lai SW, Lin CL, Liao KF. Tamoxifen use correlates with increased risk of the first episode of ischemic cerebrovascular disease in older women with breast cancer: a case-control study in Taiwan. Front Pharmacol. 2017;8:742. doi:10.3389/fphar.2017.00742 [PubMed 29089895]
  80. Lambertini M, Peccatori FA, Demeestere I, et al; ESMO Guidelines Committee. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2020;31(12):1664-1678. doi:10.1016/j.annonc.2020.09.006 [PubMed 32976936]
  81. Legha SS, Powell K, Buzdar AU, Blumenschein GR. Tamoxifen-induced hypercalcemia in breast cancer. Cancer. 1981;47(12):2803‐2806. [PubMed 7260871]
  82. Lindahl B, Andolf E, Ingvar C, Ranstam J, Willén R. Adjuvant tamoxifen in breast cancer patients affects the endometrium by time, an effect remaining years after end of treatment and results in an increased frequency of endometrial carcinoma. Anticancer Res. 2008;28(2B):1259‐1262. [PubMed 18505063]
  83. Liu CL, Yang TL. Sequential changes in serum triglyceride levels during adjuvant tamoxifen therapy in breast cancer patients and the effect of dose reduction. Breast Cancer Res Treat. 2003;79(1):11‐16. doi:10.1023/a:1023348021773 [PubMed 12779077]
  84. Loprinzi CL, Zahasky KM, Sloan JA, Novotny PJ, Quella SK. Tamoxifen-induced hot flashes. Clin Breast Cancer. 2000;1(1):52‐56. doi:10.3816/cbc.2000.n.004 [PubMed 11899390]
  85. Madabhavi I, Revannasiddaiah S, Patel A, Anand A. Toxic epidermal necrolysis with the use of tamoxifen. BMJ Case Rep. 2015;2015:bcr2014209102. doi:10.1136/bcr-2014-209102 [PubMed 25878231]
  86. Mannucci PM, Bettega D, Chantarangkul V, Tripodi A, Sacchini V, Veronesi U. Effect of tamoxifen on measurements of hemostasis in healthy women. Arch Intern Med. 1996;156(16):1806‐1810. [PubMed 8790074]
  87. Markman M, Iseminger KA, Hatch KD, et al, “Tamoxifen in Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Ancillary Report,” Gynecol Oncol, 1996, 62(1):4-6. [PubMed 8690289]
  88. Meier CR, Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol. 1998;45(6):608‐612. doi:10.1046/j.1365-2125.1998.00733.x [PubMed 9663819]
  89. Mitani N, Sakuragi S, Matsuda K, Tanaka Y, Matsui K, Shinohara K. A breast cancer patient with myelodysplastic syndrome postoperatively treated by radiation and tamoxifen administration--a case report. Gan To Kagaku Ryoho. 2006;33(6):833‐836. [PubMed 16770108]
  90. Moon Z, Hunter MS, Moss-Morris R, Hughes LD. Factors related to the experience of menopausal symptoms in women prescribed tamoxifen. J Psychosom Obstet Gynaecol. 2017;38(3):226‐235. doi:10.1080/0167482X.2016.1216963 [PubMed 27583832]
  91. Morales L, Neven P, Timmerman D, et al. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anticancer Drugs. 2004;15(8):753‐760. doi:10.1097/00001813-200409000-00003 [PubMed 15494636]
  92. Mortimer JE, Boucher L, Baty J, Knapp DL, Ryan E, Rowland JH. Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol. 1999;17(5):1488‐1492. doi:10.1200/JCO.1999.17.5.1488 [PubMed 10334535]
  93. Mourits MJ, Böckermann I, de Vries EG, et al. Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy. Br J Cancer. 2002;86(10):1546‐1550. doi:10.1038/sj.bjc.6600294 [PubMed 12085202]
  94. Muftuoglu O, Uçakhan OO, Kanpolat A. Clinical and in vivo confocal microscopy findings in patients receiving tamoxifen citrate. Eye Contact Lens. 2006;32(5):228‐232. doi:10.1097/01.icl.0000201396.74294.85 [PubMed 16974155]
  95. Mulvenna PM, Wright AJ, Podd TJ. Life-threatening tamoxifen-induced hypercalcaemia. Clin Oncol (R Coll Radiol). 1999;11(3):193‐195. doi:10.1053/clon.1999.9041 [PubMed 10465476]
  96. Murray DC, Gibson JM. Retinal changes associated with tamoxifen treatment for breast cancer. Eye (Lond). 1998;12(pt 3a):485‐486. doi:10.1038/eye.1998.114 [PubMed 9775258]
  97. Nayfield SG, Gorin MB. Tamoxifen-associated eye disease. A review. J Clin Oncol. 1996;14(3):1018‐1026. doi:10.1200/JCO.1996.14.3.1018 [PubMed 8622006]
  98. Neven P, De Muylder X, Van Belle Y, Van Hooff I, Vanderick G. Longitudinal hysteroscopic follow-up during tamoxifen treatment. Lancet. 1998;351(9095):36. doi:10.1016/s0140-6736(05)78091-0 [PubMed 9433432]
  99. Nikolic-Tomasević Z, Jelic S, Popov I, Radosavljević D, Mitrović L. Tumor 'flare' hypercalcemia--an additional indication for bisphosphonates? Oncology. 2001;60(2):123‐126. doi:10.1159/000055308 [PubMed 11244326]
  100. Nolvadex-D (tamoxifen) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; December 2021 [PubMed 11244326]
  101. Noureddin BN, Seoud M, Bashshur Z, Salem Z, Shamseddin A, Khalil A. Ocular toxicity in low-dose tamoxifen: a prospective study. Eye (Lond). 1999;13 ( Pt 6):729‐733. doi:10.1038/eye.1999.217 [PubMed 10707134]
  102. Ohara N, Kobayashi A. Two case reports of ovarian cancer after long-term tamoxifen treatment for breast cancer. J Obstet Gynaecol. 2002;22(5):572‐573. doi:10.1080/014436102760299015 [PubMed 12521448]
  103. Oien KA, Moffat D, Curry GW, et al. Cirrhosis with steatohepatitis after adjuvant tamoxifen. Lancet. 1999;353(9146):36‐37. doi:10.1016/S0140-6736(05)74872-8 [PubMed 10023952]
  104. Oktay K, Buyuk E, Libertella N, et al. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol. 2005;23(19):4347-4353. doi:10.1200/JCO.2005.05.037 [PubMed 15824416]
  105. Omar MI, Pal RP, Kelly BD, et al. Benefits of empiric nutritional and medical therapy for semen parameters and pregnancy and live birth rates in couples with idiopathic infertility: a systematic review and meta-analysis. Eur Urol. 2019;75(4):615-625. doi: 10.1016/j.eururo.2018.12.022. [PubMed 30630643]
  106. Onder Hİ, Kilic AC, Kose SA, et al. Branch retinal vein occlusion associated with tamoxifen use. Semin Ophthalmol. 2013;28(2):88‐90. doi:10.3109/08820538.2012.760618 [PubMed 23448563]
  107. Onitilo AA, Doi SA, Engel JM, Glurich I, Johnson J, Berg R. Clustering of venous thrombosis events at the start of tamoxifen therapy in breast cancer: a population-based experience. Thromb Res. 2012;130(1):27‐31. doi:10.1016/j.thromres.2011.11.025 [PubMed 22154240]
  108. Paganini-Hill A, Clark LJ. Eye problems in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2000;60(2):167‐172. doi:10.1023/a:1006342300291 [PubMed 10845279]
  109. Parkkari M, Paakkala AM, Salminen L, Holli K; Finnish Breast Cancer Group. Ocular side-effects in breast cancer patients treated with tamoxifen and toremifene: a randomized follow-up study. Acta Ophthalmol Scand. 2003;81(5):495‐499. doi:10.1034/j.1600-0420.2003.00116.x [PubMed 14510798]
  110. Pavlidis NA, Petris C, Briassoulis E, et al. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients. Cancer. 1992;69(12):2961‐2964. [PubMed 1591689]
  111. Peccatori FA, Azim HA Jr, Orecchia R, et al; ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(suppl 6):vi160-170. doi:10.1093/annonc/mdt199 [PubMed 23813932]
  112. Peccatori FA, Codacci-Pisanelli G, Mellgren G, et al. First-in-human pharmacokinetics of tamoxifen and its metabolites in the milk of a lactating mother: a case study. ESMO Open. 2020;5(5):e000859. doi:10.1136/esmoopen-2020-000859 [PubMed 33115771]
  113. Pemmaraju N, Munsell MF, Hortobagyi GN, Giordano SH. Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects. Ann Oncol. 2012;23(6):1471‐1474. doi:10.1093/annonc/mdr459 [PubMed 22085764]
  114. Perdoná S, Autorino R, De Placido S, et al. Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol. 2005;6(5):295-300. [PubMed 15863377]
  115. Perry MC, ed. Chemotherapeutic agents: tamoxifen. In: The Chemotherapy Source Book. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2012.
  116. Pinto HC, Baptista A, Camilo ME, de Costa EB, Valente A, de Moura MC. Tamoxifen-associated steatohepatitis--report of three cases. J Hepatol. 1995;23(1):95‐97. doi:10.1016/0168-8278(95)80316-5 [PubMed 8530816]
  117. Plotkin D, Lechner JJ, Jung WE, Rosen PJ. Tamoxifen flare in advanced breast cancer. JAMA. 1978;240(24):2644‐2646. [PubMed 712982]
  118. Polin SA, Ascher SM. The effect of tamoxifen on the genital tract. Cancer Imaging. 2008;8(1):135‐145. doi:10.1102/1470-7330.2008.0020 [PubMed 18603495]
  119. Rousset-Jablonski C, Thalabard JC, Gompel A. Tamoxifen contraindicated in women with hereditary angioedema? Ann Oncol. 2009;20(7):1281‐1282. doi:10.1093/annonc/mdp295 [PubMed 19482875]
  120. Roy S, Ghosh J, Shetty N, Menon MB, Ramaswamy A, Gupta S. Tamoxifen and fulvestrant induced steatohepatitis with cirrhosis: A rare case report. South Asian J Cancer. 2019;8(4):225. doi:10.4103/sajc.sajc_132_19 [PubMed 31807482]
  121. Rugo HS, Rumble RB, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. J Clin Oncol. 2016;34(25):3069-3103. doi: 10.1200/JCO.2016.67.1487. [PubMed 27217461]
  122. Salomão SR, Watanabe SE, Berezovsky A, Motono M. Multifocal electroretinography, color discrimination and ocular toxicity in tamoxifen use. Curr Eye Res. 2007;32(4):345‐352. doi:10.1080/02713680701229638 [PubMed 17453956]
  123. Saphner T, Triest-Robertson S, Li H, Holzman P. The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer. Cancer. 2009;115(14):3189‐3195. doi:10.1002/cncr.24374 [PubMed 19484789]
  124. Schiffman SS. Influence of medications on taste and smell. World J Otorhinolaryngol Head Neck Surg. 2018;4(1):84‐91. doi:10.1016/j.wjorl.2018.02.005 [PubMed 30035266]
  125. Schlegel PN, Sigman M, Collura B, et al. Diagnosis and treatment of infertility in men: AUA/ASRM guideline part II. Fertil Steril. 2021;115(1):62-69. doi:10.1016/j.fertnstert.2020.11.016 [PubMed 33309061]
  126. Schroth W, Goetz MP, Hamann U, et al, “Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen,” JAMA, 2009, 302(13):1429-36. [PubMed 19809024]
  127. Schuurman TN, Witteveen PO, van der Wall E, et al. Tamoxifen and pregnancy: an absolute contraindication? Breast Cancer Res Treat. 2019. doi: 10.1007/s10549-019-05154-7. [Epub ahead of print]. [PubMed 30707336]
  128. Serretta V, Altieri V, Morgia G, et al. A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia. Clin Genitourin Cancer. 2012;10(3):174-179. [PubMed 22502790]
  129. Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. Pediatr Crit Care Med. 2009;10(2):256-259. [PubMed 19188870]
  130. Sideras K, Ingle JN, Ames MM, et al, “Coprescription of Tamoxifen and Medications That Inhibit CYP2D6,” J Clin Oncol, 2010, 28(16):2768-76. [PubMed 20439629]
  131. Singh HK, Prasad MS, Kandasamy AK, Dharanipragada K. Tamoxifen-induced hypertriglyceridemia causing acute pancreatitis. J Pharmacol Pharmacother. 2016;7(1):38‐40. doi:10.4103/0976-500X.179365 [PubMed 27127396]
  132. Soltamox (tamoxifen citrate) [prescribing information]. Raleigh, NC: Fortovia Therapeutics Inc; June 2019.
  133. Srikantia N, Mukesh S, Krishnaswamy M. Crystalline maculopathy: a rare complication of tamoxifen therapy. J Cancer Res Ther. 2010;6(3):313‐315. doi:10.4103/0973-1482.73332 [PubMed 21119261]
  134. Srivastava A, Mansel RE, Arvind N, Prasad K, Dhar A, Chabra A. Evidence-based management of mastalgia: a meta-analysis of randomised trials. Breast. 2007;16(5):503-512. [PubMed 17509880]
  135. Stearns V, Ullmer L, López JF, Smith Y, Isaacs C, Hayes D. Hot flushes. Lancet. 2002;360(9348):1851‐1861. doi:10.1016/s0140-6736(02)11774-0 [PubMed 12480376]
  136. Steiner AZ, Terplan M, and Paulson RJ, “Comparison of Tamoxifen and Clomifene Citrate for Ovulation Induction: A Meta-Analysis,” Hum Reprod, 2005, 20(6):1511-5. [PubMed 15845599]
  137. Storen EC, Hay JE, Kaur J, Zahasky K, Hartmann L. Tamoxifen-induced submassive hepatic necrosis. Cancer J. 2000;6(2):58‐60. [PubMed 11069218]
  138. Swerdlow AJ, Jones ME; British Tamoxifen Second Cancer Study Group. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst. 2005;97(5):375‐384. doi:10.1093/jnci/dji057 [PubMed 15741574]
  139. Tamoxifen Citrate [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals; February 2022.
  140. Tang R, Shields J, Schiffman J, et al. Retinal changes associated with tamoxifen treatment for breast cancer. Eye (Lond). 1997;11(pt 3):295‐297. doi:10.1038/eye.1997.64 [PubMed 9373465]
  141. Tarafdar S, Lim LT, Collins CE, Ramaesh K. Tamoxifen keratopathy as seen with in-vivo confocal microscopy. Semin Ophthalmol. 2012;27(1-2):27‐28. doi:10.3109/08820538.2011.631510 [PubMed 22352823]
  142. Temkar S, Pujari A, Agarwal D, Chawla R. Tamoxifen maculopathy in a male patient. BMJ Case Rep. 2017;2017:bcr2017222093. doi:10.1136/bcr-2017-222093 [PubMed 28882942]
  143. Tey TT, Maung AC, Lim KW, Hsiang JC. Acute pancreatitis caused by tamoxifen-induced severe hypertriglyceridemia after 4 years of tamoxifen use. ACG Case Rep J. 2019;6(2):1‐3. doi:10.14309/crj.0000000000000025 [PubMed 31157284]
  144. Therssen R, Jansen E, Leys A, Rutten J, Meyskens J. Screening for tamoxifen ocular toxicity: a prospective study. Eur J Ophthalmol. 1995;5(4):230‐234. [PubMed 8963159]
  145. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, “Consensus on Infertility Treatment Related to Polycystic Ovary Syndrome,” Fertil Steril, 2008, 89(3):505-22. [PubMed 18243179]
  146. Thigpen T, Brady MF, Homesley HD, et al, “Tamoxifen in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study,” J Clin Oncol, 2001, 19(2):364-7. [PubMed 11208827]
  147. Török L. Treatment of oligozoospermia with tamoxifen (open and controlled studies). Andrologia. 1985;17(5):497-501. [PubMed 4061890]
  148. Ugurlu S, Karagoz A, Altin Ekin M. Ocular findings in breast cancer patients using tamoxifen. Cutan Ocul Toxicol. 2015;34(1):16‐20. doi:10.3109/15569527.2014.888078 [PubMed 24678744]
  149. US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf. Updated September 2016. Accessed October 5, 2016.
  150. Vehmanen L, Elomaa I, Blomqvist C, et al, “Tamoxifen Treatment After Adjuvant Chemotherapy Has Opposite Effects on Bone Mineral Density in Premenopausal Patients Depending on Menstrual Status,” J Clin Oncol, 2006, 24(4):675-80. [PubMed 16446340]
  151. Visvanathan K, Chlebowski RT, Hurley P, et al, “American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction,” J Clin Oncol, 2009, 27(19):3235-58. [PubMed 19470930]
  152. Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline [published correction appears in J Clin Oncol. 2013 Dec 1;31(34):4383]. J Clin Oncol. 2013;31(23):2942‐2962. doi:10.1200/JCO.2013.49.3122 [PubMed 23835710]
  153. Wang L, Miao H, Li X. Tamoxifen retinopathy: a case report. Springerplus. 2015;4:501. doi:10.1186/s40064-015-1258-2 [PubMed 26405621]
  154. Weitz IC, Israel VK, Liebman HA. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Cancer. 1997;79(10):2024‐2027. [PubMed 9149031]
  155. Wibowo E, Pollock PA, Hollis N, Wassersug RJ. Tamoxifen in men: a review of adverse events. Andrology. 2016;4(5):776‐788. doi:10.1111/andr.12197 [PubMed 27152880]
  156. Willis KJ, London DR, Bevis MA, Butt WR, Lynch SS, Holder G. Hormonal effects of tamoxifen in oligospermic men. J Endocrinol. 1977;73(1):171-178. [PubMed 323393]
  157. Yildirim Y, Inal MM, Sanci M, et al. Development of uterine sarcoma after tamoxifen treatment for breast cancer: report of four cases. Int J Gynecol Cancer. 2005;15(6):1239‐1242. doi:10.1111/j.1525-1438.2005.00170.x [PubMed 16343223]
  158. Zafeiropoulos P, Nanos P, Tsigkoulis E, Stefaniotou M. Bilateral macular edema in a patient treated with tamoxifen: a case report and review of the literature. Case Rep Ophthalmol. 2014;5(3):451‐454. doi:10.1159/000370144 [PubMed 25606038]
  159. Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. Semin Dial. 2007;20(3):217-219. [PubMed 17555487]
  160. Zhang JJ, Jacob TJ, Valverde MA, et al. Tamoxifen blocks chloride channels. A possible mechanism for cataract formation. J Clin Invest. 1994;94(4):1690‐1697. doi:10.1172/JCI117514 [PubMed 7929848]
Topic 9972 Version 359.0